News
The FDA accepted a resubmitted new drug application for reproxalap, a first-in-class investigational topical therapy for dry ...
InvestorsHub on MSN13h
Clearside Biomedical Receives Canadian Approval for XIPERE® to Treat Uveitic Macular Edema via Suprachoroidal Delivery
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical firm pioneering therapies delivered through the suprachoroidal ...
Joint Venture Partner Presents AI Technology at Roche Ophthalmology Conference – Avant Technologies, Inc. (“Avant” or the“Company”), an emerging technology company developing healthcare solutions ...
Joint Venture Partner Presents AI Technology at Roche Ophthalmology Conference - Avant Technologies, Inc. ("Avant" or the "Company"), an emerging technology company developing healthcare solutions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback